These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38234799)

  • 1. Hypothesis testing and sample size considerations for the test-negative design.
    Huo Y; Yang Y; Halloran ME; Longini IM; Dean NE
    Res Sq; 2023 Dec; ():. PubMed ID: 38234799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypothesis testing and sample size considerations for the test-negative design.
    Huo Y; Yang Y; Halloran ME; Longini IM; Dean NE
    BMC Med Res Methodol; 2024 Jul; 24(1):151. PubMed ID: 39014324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimates of 2012/13 influenza vaccine effectiveness using the case test-negative control design with different influenza negative control groups.
    Nunes B; Machado A; Guiomar R; Pechirra P; Conde P; Cristovão P; Falcão I
    Vaccine; 2014 Jul; 32(35):4443-4449. PubMed ID: 24962756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial.
    Zhang L; Wei M; Jin P; Li J; Zhu F
    Hum Vaccin Immunother; 2021 Jul; 17(7):2101-2106. PubMed ID: 33529093
    [No Abstract]   [Full Text] [Related]  

  • 6. The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings.
    Foppa IM; Ferdinands JM; Chaves SS; Haber MJ; Reynolds SB; Flannery B; Fry AM
    Int J Epidemiol; 2016 Dec; 45(6):2052-2059. PubMed ID: 26979985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Call for Caution in Use of Pertussis Vaccine Effectiveness Studies to Estimate Waning Immunity: A Canadian Immunization Research Network Study.
    Crowcroft NS; Schwartz KL; Savage RD; Chen C; Johnson C; Li Y; Marchand-Austin A; Bolotin S; Deeks SL; Jamieson FB; Drews SJ; Russell ML; Svenson LW; Simmonds K; Righolt CH; Bell C; Mahmud SM; Kwong JC
    Clin Infect Dis; 2021 Jul; 73(1):83-90. PubMed ID: 32384142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design.
    Ali M; You YA; Sur D; Kanungo S; Kim DR; Deen J; Lopez AL; Wierzba TF; Bhattacharya SK; Clemens JD
    Vaccine; 2016 Jan; 34(4):479-485. PubMed ID: 26707378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design.
    Schwartz LM; Halloran ME; Rowhani-Rahbar A; Neuzil KM; Victor JC
    Vaccine; 2017 Jan; 35(1):184-190. PubMed ID: 27876198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential test-negative design study bias in outbreak settings: application to Ebola vaccination in Democratic Republic of Congo.
    Pearson CAB; Edmunds WJ; Hladish TJ; Eggo RM
    Int J Epidemiol; 2022 Feb; 51(1):265-278. PubMed ID: 34458913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness.
    Li KQ; Shi X; Miao W; Tchetgen ET
    ArXiv; 2023 Mar; ():. PubMed ID: 35350548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.
    Turbyfill C; Adams K; Tenforde MW; Murray NL; Gaglani M; Ginde AA; McNeal T; Ghamande S; Douin DJ; Keipp Talbot H; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Clark Files D; Hager DN; Shehu A; Prekker ME; Frosch AE; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Lauring AS; Khan A; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; June Gordon A; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Rhoads JP; Lindsell CJ; Hart KW; McMorrow M; Surie D; Self WH; Patel MM
    Vaccine; 2022 Nov; 40(48):6979-6986. PubMed ID: 36374708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating Real-time Influenza Detection Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time Test-negative Design (rtTND).
    Feldstein LR; Self WH; Ferdinands JM; Randolph AG; Aboodi M; Baughman AH; Brown SM; Exline MC; Files DC; Gibbs K; Ginde AA; Gong MN; Grijalva CG; Halasa N; Khan A; Lindsell CJ; Newhams M; Peltan ID; Prekker ME; Rice TW; Shapiro NI; Steingrub J; Talbot HK; Halloran ME; Patel M;
    Clin Infect Dis; 2021 May; 72(9):1669-1675. PubMed ID: 32974644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials.
    De Serres G; Skowronski DM; Wu XW; Ambrose CS
    Euro Surveill; 2013 Sep; 18(37):. PubMed ID: 24079398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
    Mésidor M; Liu Y; Talbot D; Skowronski DM; De Serres G; Merckx J; Koushik A; Tadrous M; Carazo S; Jiang C; Schnitzer ME
    Vaccine; 2024 Feb; 42(5):995-1003. PubMed ID: 38072756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the bias of estimates of influenza vaccine effectiveness from test-negative studies.
    Ainslie KEC; Shi M; Haber M; Orenstein WA
    Vaccine; 2017 Dec; 35(52):7297-7301. PubMed ID: 29146382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of seasonal influenza vaccine effectiveness using data collected in primary care in France: comparison of the test-negative design and the screening method.
    Vilcu AM; Souty C; Enouf V; Capai L; Turbelin C; Masse S; Behillil S; Valette M; Guerrisi C; Rossignol L; Blanchon T; Lina B; Hanslik T; Falchi A
    Clin Microbiol Infect; 2018 Apr; 24(4):431.e5-431.e12. PubMed ID: 28899840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of summer programmes on the outcomes of disadvantaged or 'at risk' young people: A systematic review.
    Muir D; Orlando C; Newton B
    Campbell Syst Rev; 2024 Jun; 20(2):e1406. PubMed ID: 38873396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19.
    Stuurman AL; Bollaerts K; Alexandridou M; Biccler J; Díez Domingo J; Nohynek H; Rizzo C; Turunen T; Riera-Montes M;
    Vaccine; 2020 Sep; 38(41):6455-6463. PubMed ID: 32778474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for SARS-CoV-2 infection: a test-negative case-control study with additional population controls in Norway.
    Sarjomaa M; Zhang C; Tveten Y; Kersten H; Reiso H; Eikeland R; Kongerud J; Berg KK; Thilesen C; Nordbø SA; Aaberge IS; Vandenbroucke J; Pearce N; Fell AKM
    BMJ Open; 2024 Jan; 14(1):e073766. PubMed ID: 38191258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.